Kura Oncology, Inc. KURA
9.88 USD +0.09 (+0.92%)
At closeNov 3, 2026, 5:13 PM EST
9.99 +0.11 +1.11%
After hours · Nov 3, 5:13 PM ET
9.77 Day range 10.17
7.36 52-week range 13.90
- YTD
- -4.91%
- 1 year
- +1.13%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 32.00 +223.9% upside
Now 9.88
- Target (low)
- 15.00
- Target (mean)
- 32.00
- Target (high)
- 76.00
Ratings (0m) 15 14 buy · 1 hold · 0 sell
- Strong buy2
- Buy12
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 15
- 1 month ago 15
- 2 months ago 15
- 3 months ago 15
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.80667 | -0.99 – -0.70 | -0.85 | +5.1% | 23.80M | +14.7% | 9 |
| Next quarter | -0.78222 | -0.95 – -0.68 | -0.92 | +15.0% | 33.54M | +93.5% | 9 |
| Current year | -3.16 | -3.48 – -2.98 | -3.18 | +0.5% | 96.57M | +43.1% | 9 |
| Next year | -2.30 | -3.26 – -1.58 | -3.16 | +27.4% | 212.18M | +119.7% | 9 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 24, 2026 | Citizens | Reiterated | Market Outperform | Market Outperform |
| Aug 13, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jul 28, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Jun 15, 2026 | Citizens | Reiterated | Market Outperform | Market Outperform |
| Apr 14, 2026 | Lake Street | Initiated | — | Buy |
| Mar 24, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Mar 13, 2026 | UBS | Maintained | Buy | Buy |
| Mar 6, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jan 13, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Jan 13, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 24, 2025 | Barclays | Maintained | Overweight | Overweight |
| Nov 14, 2025 | UBS | Maintained | Buy | Buy |
| Nov 14, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Oct 20, 2025 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Oct 20, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 30, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 4, 2025 | Guggenheim | Initiated | — | Neutral |
| Aug 11, 2025 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Jun 26, 2025 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Jun 20, 2025 | Wedbush | Reiterated | Outperform | Outperform |
| Jun 4, 2025 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| May 19, 2025 | Mizuho | Maintained | Outperform | Outperform |
| May 2, 2025 | Barclays | Maintained | Overweight | Overweight |
| Apr 29, 2025 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Apr 28, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 6, 2025 | UBS | Maintained | Buy | Buy |
| Feb 27, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 6, 2025 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Feb 6, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Feb 6, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |